All In Biotech

Drug Trial Radar · NCT02347657

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor

A Phase 3, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation

Last checked: Nov 19, 2026Latest source record: Jun 12, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 510 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

510

Actual

Start

Jan 2015

Primary completion

Jan 20, 2017

Study completion Jan 20, 2017

Sponsor

Lead sponsor
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
Sponsor type
Industry
First posted
Jan 27, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3, randomized, double blind, placebo controlled, parallel group, multicenter study in people with cystic fibrosis (CF) who are homozygous for the F508del CF transmembrane conductance regulator (CFTR) gene mutation.

Conditions

  • Cystic Fibrosis

Interventions

  • VX-661 Plus Ivacaftor CombinationDrug

    FDC tablet, oral use

  • IvacaftorDrug

    Tablet, oral use

  • VX-661 Plus Ivacaftor Combination PlaceboDrug

    FDC tablet, oral use

  • Ivacaftor placeboDrug

    Tablet, oral use

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Absolute Change From Baseline (Day 1) in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) Through Week 24Time frame: Day 1, Through Week 24

Locations

74 sites in 12 countries. Site status is shown where the registry gives one.

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Long Beach, California

  • Site not named

    Denver, Colorado

  • Site not named

    Orlando, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    Chicago, Illinois

  • Site not named

    Peoria, Illinois

  • Site not named

    Boston, Massachusetts

  • Site not named

    Minneapolis, Minnesota

  • Site not named

    St Louis, Missouri

  • Site not named

    Manchester, New Hampshire

  • Site not named

    Long Branch, New Jersey

  • Site not named

    Albuquerque, New Mexico

  • Site not named

    Albany, New York

  • Site not named

    Buffalo, New York

  • Site not named

    New Hyde Park, New York

  • Site not named

    Rochester, New York

  • Site not named

    Syracuse, New York

  • Site not named

    Akron, Ohio

  • Site not named

    Columbus, Ohio

  • Site not named

    Oklahoma City, Oklahoma

  • Site not named

    Charleston, South Carolina

  • Site not named

    Sioux Falls, South Dakota

  • Site not named

    Fort Worth, Texas

  • Site not named

    Tyler, Texas

  • Site not named

    Seattle, Washington

  • Site not named

    Milwaukee, Wisconsin

  • Site not named

    Calgary, Alberta, Canada

  • Site not named

    Vancouver, British Columbia, Canada

  • Site not named

    Halifax, Nova Scotia, Canada

  • Site not named

    Toronto, Ontario, Canada

  • Site not named

    Montreal, Quebec, Canada

  • Site not named

    Copenhagen O, Denmark

  • Site not named

    Marseille, Bouches-du-Rhone, France

  • Site not named

    Roscoff, Finistere, France

  • Site not named

    Bordeaux, Girande, France

  • Site not named

    Lille, Nord, France

  • Site not named

    Paris, Paris, France

  • Site not named

    Pierre-Bénite, Rhone, France

  • Site not named

    Berlin, Germany

Showing 40 of 74 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.